Harrow (HROW) vs Janux Therapeutics (JANX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Janux Therapeutics (JANX) has outperformed Harrow (HROW) over the past year, losing 21.0% versus a loss of 26.9%. Over five years, HROW leads with a +209.6% price change compared with -15.2% for JANX. Harrow is the larger company by market cap ($1.15 billion vs $1.10 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HROW | JANX |
|---|---|---|
| Share price | $30.62 | $17.92 |
| Market cap | $1.15B | $1.10B |
| 1-day change | +0.89% | +6.73% |
| YTD return | -37.51% | +29.86% |
| 1-year return | -26.92% | -21.02% |
| 5-year return | +209.61% | -15.19% |
| Forward P/E | 11.04 | — |
| EPS (TTM) | $-0.99 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $54.85 | $35.34 |
| 52-week low | $28.54 | $12.12 |
| Distance from 52-week high | -44.18% | -49.29% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +112.28% | +102.23% |
| Average volume | 552.72K | 830.67K |
| Shares outstanding | 37.49M | 61.14M |
| Employees | 373 | 113 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Harrow
HROW stock →Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Healthcare · Drug Manufacturers - Specialty & Generic · 373 employees
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Healthcare · Biotechnology · 113 employees
HROW vs JANX FAQ
Which is bigger, Harrow or Janux Therapeutics?
Harrow (HROW) is larger, with a market capitalization of $1.15B compared with $1.10B for Janux Therapeutics (JANX).
Which stock has performed better over the past year, HROW or JANX?
JANX returned -21.02% over the past 12 months, compared with -26.92% for HROW (price return, excluding dividends). Past performance does not predict future results.
Are Harrow and Janux Therapeutics in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Harrow and Biotechnology for Janux Therapeutics.